Rare diseases
Investigational molecules
Locations
239 conditions with trials, the busiest first
357 trials across Europe, recruiting first
Phase 1/2 Study of CR-001 Safety and Dose Finding in Adults with Locally Advanced or Metastatic Solid Tumors
FranceEfficacy and safety of human alpha1‑proteinase inhibitor weekly infusions in adults with alpha1 antitrypsin deficiency–related emphysema
DenmarkA study of belzutifan and lenvatinib for patients with von Hippel-Lindau disease-associated tumors or other specific solid tumors.
BelgiumA study of pumitamig and ipilimumab in patients with advanced or unresectable liver cancer
FranceA study to evaluate the effectiveness and safety of vamifeport in adults with hereditary hemochromatosis
AustriaA study to investigate the safety and effects of ceralasertib, tremelimumab, and durvalumab in adults with various solid tumors
PolandA study of rilvegostomig, cisplatin, and gemcitabine compared to durvalumab and a drug combination for adults with advanced biliary tract cancer
BelgiumEvaluating the use of technetium (99mTc) galactosyl serum albumin to predict complications in patients undergoing surgery for liver tumors
DenmarkA study comparing different zinc doses for the treatment of Wilson disease in healthy participants.
DenmarkA study to evaluate the effectiveness and safety of ursodeoxycholic acid in patients with hepatorenal polycystic diseases.
SpainN1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD
AustriaA study comparing brelovitug to bulevirtide for treating chronic hepatitis delta infection in patients currently receiving bulevirtide
AustriaThe therapies tested most often in Hepatobiliary disorders trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
